

# Hutchison China MediTech

WCLC update

## WCLC highlights savolitinib combination potential

Data presented at the World Conference on Lung Cancer (WCLC) on combination approaches to treat resistant EGFR-driven non-small cell lung cancer (NSCLC) highlight a widening of the patient population that could be eligible to receive savolitinib in combination with either Tagrisso or Iressa. Partner AZN now has the data set to make a decision on global Phase III trials and evaluate breakthrough therapy designation (BTD) potential in both 2L and 3L EGFR-resistant NSCLC; in our view, data to date supports both. BTD could offer earlier entry into the US market. Furthermore, Phase II data presented on fruquintinib in combination with Iressa (first line EGFRm NSCLC) showed encouraging efficacy and acceptable safety. We place our forecasts and valuation under review as we revisit our peak sales assumptions.

Year end	Revenue (\$m)	Net profit* (\$m)	EPS* (c)	DPS (c)	P/E (x)	Yield (%)
12/15	178.2	8.0	14.6	0.0	N/A	N/A
12/16	216.1	11.7	19.6	0.0	N/A	N/A
12/17e	N/A	N/A	N/A	N/A	N/A	N/A
12/18e	N/A	N/A	N/A	N/A	N/A	N/A

Note: \*Net profit and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

## Savolitinib: Data in NSCLC demonstrates potential

Combinations of targeted therapies (TKI, monoclonal antibodies and immunotherapies) and chemotherapy is increasingly becoming the best approach to treating the complex and constantly mutating disease that is cancer. Savolitinib has the potential to be utilised across all lines of treatment in all MET-driven patients either as monotherapy or in combination. Data presented at the WCLC demonstrated positive efficacy for savolitinib in combination with Tagrisso or Iressa in EGFR-mutant, T790M +/-, MET-positive patients. Additionally, patients who had been previously treated with a third-generation T790M TKI (Tagrisso refractory) achieved a 33% PR (n=64). The importance of the data presented at WCLC is twofold; it underpins the scientific rationale at HCM in designing highly specific molecules that can be used both as monotherapy and in combinations to treat patients that are refractory to available EGFR therapies thereby opening up new treatment paradigms.

## Fruquintinib: Impressive PR observed to date

Data were presented from an ongoing Phase II trial evaluating fruquintinib (VEGFR inhibitor) in combination with Iressa in EGFR-mutant NSCLC patients as first line therapy which supports this unique VEGFR inhibitor's role in combination therapy. 13/17 patients (76.5%) had a partial response and four had stable disease (23.5%). No patients as of the data cut-off had progressive disease. Overall, an acceptable safety profile was observed.

## Valuation: Under review

We place our forecasts and valuation under review.

Pharma &amp; biotech

18 October 2017

**Price** **4,500p**
**Market cap** **£2,757m**

US\$1.25/£

Net cash (\$m) as of 30 June 2017 65.7

Shares in issue 60.7m

Free float 39.6%

Code HCM

Primary exchange AIM

Secondary exchange NASDAQ

### Share price performance



% 1m 3m 12m

Abs 22.7 30.6 147.7

Rel (local) 17.8 28.2 126.6

52-week high/low 4,563p 1,818p

### Business description

Hutchison China MediTech (Chi-Med; HCM) is an innovative China-based biopharmaceutical company targeting the global market for novel, highly selective oral oncology, and immunology drugs. Its established commercial platform business in China is growing ahead of the market.

### Next events

AZN decision on savolitinib PIII NSCLC 2017

Fruquintinib China NDA approval and launch 2018

### Analysts

Dr Susie Jana +44 (0)20 3077 5700

Dr Daniel Wilkinson +44 (0)20 3077 5734

[healthcare@edisongroup.com](mailto:healthcare@edisongroup.com)
[Edison profile page](#)

**Hutchison China MediTech is a research client of Edison Investment Research Limited**


## Savolitinib demonstrates utility in NSCLC

At the recent 18th (2017) WCLC, preliminary data were presented on two separate Phase Ib/II proof-of-concept clinical trials assessing savolitinib in combination with AstraZeneca's Tagrisso and Iressa for NSCLC patients. The data presented give an important insight into the potential utility of savolitinib in patients who have progressed following treatment with a first- (Iressa) or third- (Tagrisso) generation EGFR inhibitor. Patients treated were EGFR mutation-positive and presented with T790M and/or MET-driven disease, and, in our view, the data highlight savolitinib's potential for use in second- and third-line MET-amplified, EGFR-mutant patients, irrespective of EGFR inhibitor utilised and T790M status. Secondary resistance mechanisms in cancer patients that have received mutation-targeted medicines are emerging and as such savolitinib's place in addressing resistance in MET-driven lung cancers is becoming increasingly evident. The importance of the overall data is the potential widening of the NSCLC patient population that could be eligible to receive savolitinib as combination therapy. The safety profile across both the Iressa/savolitinib and Tagrisso/savolitinib combinations was consistent with the known safety profiles for each class of drugs.

## Tagrisso and Savolitinib combination looks to US market

The Phase Ib/II TATTON trial is testing the combination of savolitinib and Tagrisso in patients with advanced EGFR-mutant MET-amplified NSCLC. Patients fell into three distinct groups: those who had prior third-generation T790M EGFR TKI treatment; those who had no prior third-generation T790M EGFR TKI treatment but were T790m-positive; and those who had also had no prior third-generation T790M EGFR TKI treatment but were T790m-negative. Sixty-four MET-positive patients were eligible for overall analysis of preliminary anti-tumour activity; of which 47 patients were confirmed centrally and 17 were confirmed locally (at the clinical site). Exhibit 1 highlights the preliminary anti-tumour activity in the savolitinib and Tagrisso group (based on all 64 C-MET positive patients). Patients with centrally confirmed MET-positive disease who had been previously treated with a third-generation T790M TKI had a 28% PR. This compared with 57% who had not been treated with a T790M TKI but were T790M-positive, and 53% who were T790M-negative. There were no complete responses in any of the patient groups, a result that is to be expected in this patient population with this class of drugs.

**Exhibit 1: Preliminary anti-tumour activity of the combination of savolitinib and Tagrisso in patients with centrally and locally confirmed MET-positive NSCLC**



Source: Ahn M-J, et al. TATTON Phase Ib Expansion Cohort: Osimertinib Plus Savolitinib for Patients with EGFR-mutant MET-amplified NSCLC After Progression on Prior EGFR-TKI. Abstract #8985. Presented at the World Lung Cancer Congress 2017, Yokohama, Japan, 15-18 October 2017.


While these data demonstrate the potential of savolitinib in second- and third-line settings, the expected move of Tagrisso to a first-line treatment following the positive [FLAURA data](#) could open up further opportunities for savolitinib as 2L treatment option in Tagrisso refractory patients. Data presented so far by HCM appear to indicate that around 30% of patients are MET-positive after Tagrisso treatment, compared with around 6% who are MET-positive and T790M-positive, and 10% who are MET-positive and T790M-negative after first-line, first-generation EGFR TKI (Iressa/Tarceva) treatment. While the percentage of patients who are MET-positive once Tagrisso is utilised as first-line treatment is unknown at this time, these data suggest that a larger patient population may be addressable by savolitinib once this shift in standard of care is made ie the use of savolitinib (2L and 3L) in Tagrisso resistance patient populations.

## Opportunities in Asia in combination with first-generation EGFR inhibitors

We anticipate HCM to move forward with a strategy in Asia for NSCLC that focuses on combinations with first-generation TKI inhibitors such as AstraZeneca's Iressa and Roche's Tarceva, which are now off-patent in China. The Phase Ib/II expansion cohort tested a combination of savolitinib and Iressa in EGFR-mutant, MET-amplified NSCLC patients.

Preliminary anti-tumour activity was available in all 51 patients who were treated. 52% (n=12/23) who were T790M-negative, achieved a PR an expected result as Tagrisso (or another T790M targeting compound) was not utilised. As demonstrated in Exhibit 2, many of the responding patients in the T790M-negative arm are still receiving ongoing treatment and have ongoing partial responses.

**Exhibit 2: Duration of treatment in MET-amplified, EGFR mutation-positive patients who are treated with a combination of savolitinib and Iressa, N = 51**



Source: Hutchison China Meditech reports

As expected response in T790M-positive patients was low, 9% (n=2/23) achieving a PR, we highlight that Iressa was not designed to address this patient subgroup (Tagrisso is now approved for this subgroup of patients). Stable disease at and beyond six weeks was similar in both groups, achieved in 30% (n=7/23) of T790M-negative patients and 39% (n=9/23) of T790M-positive patients. However, deaths occurred at a substantially increased rate in the T790M-positive arm (30% vs 13% in T790M-negative patients).

## Fruquintinib

Fruquintinib is an oral small molecule that is a highly selective VEGFR1, VEGFR2 and VEGFR3 inhibitor, which in preclinical trials demonstrated fewer off-target toxicities, allowing higher drug exposure that translates to 24 hours a day VEGFR receptor inhibition. Fruquintinib's unique

selectivity (lack of CYP450 inhibition/inducing) is favourable for potential in combination treatment regimens, given that many drugs are metabolised through the cytochrome p450 enzyme pathway.

Data were presented from an ongoing Phase II trial testing fruquintinib (VEGFR inhibitor) in combination with Iressa in EGFR-mutant NSCLC patients which supports this unique VEGFR inhibitor's role in combination therapy. The trial tested fruquintinib at 4mg or 5mg once daily for three weeks on/one week off in combination with 250mg of Iressa once daily. Seventeen patients were eligible for efficacy evaluation, of which 13 (four PRs not confirmed as of data cut-off) patients (76.5%) had a partial response and four had stable disease (23.5%). No patients as of data cut-off had progressive disease and the median time to response was 56 days. 4mg dosing of Fruquintinib was determined to be the most suitable dose for further investigation as liver enzyme elevation was observed at 5mg. 8/26 (30.8%) patients reported a Grade 3-4 AEs, five of which were increases in alanine transaminase (ALT) as result of damage to the liver. Previously as a monotherapy, fruquintinib (plus best supportive care) in a Phase II trial in third-line NSCLC demonstrated median progression-free survival of 3.81 months vs 1.15 months for placebo (HR=0.275,  $p<0.001$ ).

**Exhibit 3: Financial summary**

\$000s	2014		2015		2016	
		US GAAP		US GAAP		US GAAP
December						
<b>PROFIT &amp; LOSS</b>						
Revenue		87,329		178,203		216,080
Cost of Sales		(58,849)		(110,777)		(156,328)
Gross Profit		28,480		67,426		59,752
Research and development		(29,914)		(47,368)		(66,871)
Other overheads		(16,825)		(29,829)		(39,578)
EBITDA		(16,994)		(7,756)		(44,264)
Operating Profit (before amort. and except.)		(18,259)		(9,771)		(46,697)
Intangible Amortisation		0		0		0
Operating Profit		(18,259)		(9,771)		(46,697)
Net Interest		(957)		(953)		(1,129)
Exceptionals		0		0		0
Profit Before Tax (norm)		(19,957)		(10,540)		(47,356)
Profit Before Tax (reported)		(19,957)		(10,540)		(47,356)
Tax		(1,343)		(1,605)		(4,331)
Equity investments, after tax		15,180		22,572		66,244
Profit After Tax (norm)		(6,120)		10,427		14,557
Profit After Tax (reported)		(6,120)		10,427		14,557
Minority		(3,220)		(2,434)		(2,859)
Discontinued operations		2,034		0		0
Net profit (norm)		(9,340)		7,993		11,698
Net profit (reported)		(7,306)		7,993		11,698
Average Number of Shares Outstanding (m)		52.6		54.7		59.7
EPS - normalised (c)		(17.8)		14.6		19.6
EPS - normalised and fully diluted (c)		(17.8)		14.6		19.5
EPS - (reported) (c)		(13.9)		14.6		19.6
Average number of ADS outstanding (m)		105.1		109.3		119.4
Earnings per ADS - normalised (\$)		(0.09)		0.07		0.10
Earnings per ADS (\$)		(0.07)		0.07		0.10
<b>BALANCE SHEET</b>						
Fixed Assets		120,992		140,087		175,057
Intangible Assets		4,096		3,903		3,606
Tangible Assets		7,482		8,507		9,954
Investments		109,414		127,677		161,497
Current Assets		89,842		89,675		167,380
Stocks		4,405		9,555		12,822
Debtors		27,924		38,628		49,349
Cash		38,941		31,949		79,431
St investments		12,179		0		24,270
Other		6,393		9,543		1,508
Current Liabilities		(75,299)		(81,062)		(95,119)
Creditors		(20,427)		(24,086)		(35,538)
Short term borrowings		(26,282)		(23,077)		(19,957)
Other		(28,590)		(33,899)		(39,624)
Long Term Liabilities		(37,584)		(46,415)		(43,258)
Long term borrowings		(26,923)		(26,923)		(26,830)
Other long term liabilities		(10,661)		(19,492)		(16,428)
Net Assets		97,951		102,285		204,060
Minority		(17,764)		(18,921)		(19,790)
Shareholder equity		80,187		83,364		184,270
<b>CASH FLOW</b>						
Operating Cash Flow		8,359		(9,385)		(9,569)
Net Interest		0		0		0
Tax		0		0		0
Capex		(3,729)		(3,324)		(4,327)
Acquisitions/disposals		689		0		0
Dividends		(1,179)		(590)		(564)
Equity financing and capital movements		5,860		(1,676)		97,076
Other		(12,179)		12,179		(29,270)
Net Cash Flow		(2,179)		(2,796)		53,346
Opening net debt/(cash and ST investments)		4,645		2,085		18,051
Increase/(decrease) in ST investments		12,179		(12,179)		24,270
Other		(7,440)		(991)		(2,651)
Closing net debt/(cash and ST investments)		2,085		18,051		(56,914)

Source: Hutchison China MediTech reports, Edison Investment Research. Note: Equity investments after tax include the net profit contribution from JVs.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the [Financial Conduct Authority](#). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. [www.edisongroup.com](http://www.edisongroup.com)

#### DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been commissioned by Hutchison China MedTech and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited ("FTSE") © FTSE 2017. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.